Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

Baseline characteristic Study 1 Study 2a
  V930 DNA-EP V930 DNA-EP V932 Ad V932 Ad
  0.25 mg 2.5 mg 0.5 × 109vg/injection 0.5 × 1011vg/injection
  (n=6) (n=22) (n=6) (n=5)
Age, years (mean ± SD) 66.8 ± 9.2 58.6 ± 15.9 58.8 ± 12.9 54.4 ± 8.6
Gender, n (%)     
 Male 2 (33) 8 (36) 2 (33) 4 (80)
 Female 4 (67) 14 (64) 4 (67) 1 (20)
Race, n (%)     
 White 6 (100) 21 (96) 5 (83) 5 (100)
 Other 0 1 (4.5) 1 (16.7) 0
KPS, n (%)     
 100 6 (100) 17 (77) 6 (100) 5 (100)
 90 0 5 (23) 0 0
Tumor diagnosis, n (%)     
 Adenocarcinoma NOS 1 (17) 1 (5) 0 0
 Breast cancer 0 7 (32) 3 (50) 0
 Colorectal cancer 4 (67) 6 (27) 1 (17) 1 (20)
 Non-small cell lung cancer 1 (17) 5 (23) 2 (33) 1 (20)
 Ovarian cancer 0 1 (5) 0 0
 Pancreatic cancer 0 1 (5) 0 0
 Squamous cell carcinoma 0 1 (5) 0 0
 NOS 0 0 0 1 (20)
 Renal cancer 0 0 0 2 (40)
 Bladder cancer 0 0 0 1 (20)
Prior lines of chemotherapy, n (%)     
 0 0 0 0 1 (20)
 1 6 (100) 11 (50) 2 (33) 1 (20)
 2 0 5 (23) 3 (50) 1 (20)
 ≥3 0 6 (27) 1 (17) 2 (40)
Stage IV cancer 0 (0) 11 (50) 4 (67) 3 (60)
  1. aSix eligible patients from Study 1 were enrolled into Study 2. Therefore, only 5 patients that had not previously participated in Study 1 were enrolled into Study 2. Overall 33 patients (not 39) were enrolled in both studies.
  2. KPS: Karnofsky performance status; NOS, not otherwise specified; SD, standard deviation.